Dabrafenib is almost 20 times more specific for BRAF V600E mutants with respect to BRAF WT in multiple cancer cell lines with a lower IC50 in comparison with other BRAFi and displays inhibition in cell lines containing alternative oncogenic BRAF mutations [83]. Here, BRAF is linked to cancer.